Page 117 - 《中国药房》2026年2期

The Cochrane Collaboration’s tool for assessing risk of triple-negative breast cancer（TNBC）[J]. J Clin Oncol，
bias in randomised trials[J]. BMJ，2011，343：d5928. 2021，39（Suppl. 15）：506.
[ 9 ] SCHMID P，CORTES J，PUSZTAI L，et al. Pembroli‐ [17] GIANNI L，PIENKOWSKI T，IM Y H，et al. Efficacy and
zumab for early triple-negative breast cancer[J]. N Engl J safety of neoadjuvant pertuzumab and trastuzumab in
Med，2020，382（9）：810-821. women with locally advanced，inflammatory，or early
[10] CHEN L，LI H，ZHANG H，et al. Camrelizumab vs pla‐ HER2-positive breast cancer（NeoSphere）：a randomised
cebo in combination with chemotherapy as neoadjuvant multicentre，open-label，phase 2 trial[J]. Lancet Oncol，
treatment in patients with early or locally advanced triple- 2012，13（1）：25-32.
negative breast cancer：the CamRelief randomized clinical [18] CORTAZAR P，ZHANG L J，UNTCH M，et al. Patho-
trial[J]. JAMA，2025，333（8）：673-681. logical complete response and long-term clinical benefit
[11] MITTENDORF E A，ASSAF Z J，HARBECK N，et al. in breast cancer：the CTNeoBC pooled analysis[J]. Lancet，
Peri-operative atezolizumab in early-stage triple-negative 2014，384（9938）：164-172.
breast cancer：final results and ctDNA analyses from the [19] RIZZO A，CUSMAI A，MASSAFRA R，et al. Patho-
randomized phase 3 IMpassion031 trial[J]. Nat Med， logical complete response to neoadjuvant chemoimmuno‐
therapy for early triple-negative breast cancer：an updated
2025，31（7）：2397-2404.
[12] MITTENDORF E A，ZHANG H，BARRIOS C H，et al. meta-analysis[J]. Cells，2022，11（12）：1857.
[20] VANHERSECKE L，BRUNET M，GUÉGAN J P，et al.
Neoadjuvant atezolizumab in combination with sequential
Mature tertiary lymphoid structures predict immune
nab-paclitaxel and anthracycline-based chemotherapy ver‐
checkpoint inhibitor efficacy in solid tumors indepen‐
sus placebo and chemotherapy in patients with early-stage
dently of PD-L1 expression[J]. Nat Cancer，2021，2（8）：
triple-negative breast cancer（IMpassion031）：a ran‐
794-802.
domised，double-blind，phase 3 trial[J]. Lancet，2020，396
[21] LI L Y，ZHANG F，LIU Z Y，et al. Immunotherapy for
（10257）：1090-1100.
triple-negative breast cancer：combination strategies to
[13] NANDA R，LIU M C，YAU C，et al. Effect of pembroli‐
improve outcome[J]. Cancers，2023，15（1）：321.
zumab plus neoadjuvant chemotherapy on pathologic com‐
[22] HE Q，PENG Y C，SUN J，et al. Platinum-based chemo‐
plete response in women with early-stage breast cancer：
therapy and immunotherapy in early triple-negative breast
an analysis of the ongoing phase 2 adaptively randomized
cancer：a meta-analysis and indirect treatment comparison
I-SPY2 trial[J]. JAMA Oncol，2020，6（5）：676-684.
[J]. Front Oncol，2021，11：693542.
[14] GEYER C，TANG G，NEKLJUDOVA V，et al. Abstract
[23] YANG Y L，LI H F，YANG W，et al. Improving efficacy
GS3-05：NSABP B-59/GBG-96-GeparDouze：a rando-
of TNBC immunotherapy：based on analysis and sub-
mized double-blind phase Ⅲ clinical trial of neoadjuvant
typing of immune microenvironment[J]. Front Immunol，
chemotherapy with atezolizumab or placebo followed by
2024，15：1441667.
adjuvant atezolizumab or placebo in patients with stage Ⅱ [24] HOLDER A M，DEDEILIA A，SIERRA-DAVIDSON K，
and Ⅲ triple-negative breast cancer[J]. Clin Cancer Res，
et al. Defining clinically useful biomarkers of immune
2025，31（Suppl. 12）：GS3-5-GS3-05.
checkpoint inhibitors in solid tumours[J]. Nat Rev Cancer，
[15] LOIBL S，UNTCH M，BURCHARDI N，et al. A ran‐ 2024，24（7）：498-512.
domised phase Ⅱ study investigating durvalumab in addi‐ [25] HUOBER J，VAN MACKELENBERGH M，SCHNEEWEISS
tion to an anthracycline taxane-based neoadjuvant therapy A，et al. Identifying breast cancer patients at risk of relapse
in early triple-negative breast cancer：clinical results and despite pathological complete response after neoadjuvant
biomarker analysis of GeparNuevo study[J]. Ann Oncol， therapy[J]. NPJ Breast Cancer，2023，9（1）：23.
2019，30（8）：1279-1288. [26] MIAO K，ZHANG L. Pathogenesis，pathological charac‐
[16] LOIBL S，SCHNEEWEISS A，HUOBER J B，et al. Dur‐ teristics and individualized therapy for immune-related
valumab improves long-term outcome in TNBC：results adverse effects[J]. Chin Med J Pulm Crit Care Med，2023，
from the phase Ⅱ randomized GeparNuevo study inves- 1（4）：215-222.
tigating neoadjuvant durvalumab in addition to an anthra‐ （收稿日期：2025-09-08 修回日期：2026-01-05）
cycline/taxane based neoadjuvant chemotherapy in early （编辑：陈 宏）

中国药房 2026年第37卷第2期 China Pharmacy 2026 Vol. 37 No. 2 · 243 ·